Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06074185
Other study ID # 00138724
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 19, 2024
Est. completion date September 7, 2025

Study information

Verified date February 2024
Source Oregon Health and Science University
Contact Matthew L Hansen, MD, MCR
Phone 503494-7500
Email hansemat@ohsu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over 200,000 children have a 911 Emergency Medical Services (EMS) activation for respiratory distress each year, most of whom have acute wheezing. Early treatment in the prehospital setting could more rapidly relieve respiratory distress symptoms, prevent hypoxia, reduce invasive interventions, and reduce the need to be hospitalized, thereby facilitating earlier return to normal daily activities. Preliminary data from one site found hospital admission was reduced from 30% to 21% among children when an EMS system introduced a pediatric asthma protocol with oral dexamethasone. The current standard for Emergency Department (ED) treatment for acute wheezing for children two and older includes inhaled ipratropium and dexamethasone. These treatments have a longstanding history of safety and are effective in preventing hospitalization when used early in the ED. Specific treatment protocols generally direct prehospital care. Ipratropium and dexamethasone are recommended by national EMS organizations that develop model protocols for prehospital care. However, only 25% of EMS agencies from large US metropolitan areas allow ipratropium, and only 10% include dexamethasone in their treatment protocols. A clinical trial is critically needed to evaluate whether the significant EMS resources required to implement interventions for children with life-threatening wheezing that have proven benefit in the ED result in improved patient outcomes. The overall objective of this three-site pilot trial is to address specific questions related to the implementation of the study and ensure its feasibility. The study will be conducted in the Pediatric Emergency Care Applied Research Network (PECARN) EMS Affiliates (EMSAs). The investigators will include patients aged 2-17 who have a 911 call for acute life-threatening wheezing. The specific aims are 1) to develop and produce a prehospital checklist for the treatment bundle, including ipratropium and dexamethasone, 2) to determine the feasibility of collecting patient outcomes for wheezing children treated in the EMS system, and 3) to evaluate the implementation of the EMS treatment bundle and checklist using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Our overall hypothesis is that the study will be feasible to implement. This study will provide the necessary data to ensure the eventual trial is feasible, primarily by establishing the ability to measure the outcomes of interest as well as evaluating implementation. This study is innovative by focusing on pediatric care in the prehospital environment, a critical component of our emergency care system that is often neglected in research.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 7, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: 1. Ages 2-17 years; AND 2. Transported by EMS through 911 activation; AND 3. Prior history of wheeze/asthma, current asthma symptoms (dyspnea or wheeze); AND 4. At least 4 of the following: - Visible use of accessory muscles/retractions - Inspiratory and expiratory wheezing or silent chest - Abnormal respiratory rate for age - For < 6 years = 46 breaths/min - For = 6 years = 36 breaths/min - Agitation, drowsiness, or confusion - Oxygen saturation < 93% on room air Exclusion Criteria: 1. History of albuterol, ipratropium, or dexamethasone allergy 2. Known or suspected pregnancy 3. Prisoner 4. Croup 5. Suspected airway foreign body 6. Respiratory distress not due to bronchospasm/wheeze 7. Parent, legally authorized representative (LAR), subject, and/or family member objects to participation prior to treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ipratropium Bromide
The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.

Locations

Country Name City State
United States University at Buffalo Buffalo New York
United States Mecklenburg County EMS Charlotte North Carolina
United States University of Utah Salt Lake City Utah

Sponsors (4)

Lead Sponsor Collaborator
Oregon Health and Science University University at Buffalo, University of Utah, Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Rate of successful primary and secondary outcome measurement among participants We will evaluate the feasibility of collecting the main study outcomes among study participants Through 8 days after enrollment
Other Proportion of patients who require a critical care intervention Use of bag mask ventilation, non-invasive positive pressure ventilation, endotracheal intubation, high-flow nasal cannula, Extra Corporeal Membrane Oxygenation (ECMO), and Cardio Pulmonary Resuscitation (CPR) Within one week of the index EMS encounter
Primary Proportion of patients admitted to the hospital in each group Whether or not the patient was admitted to the hospital after the index EMS encounter Within 24 hours of the index EMS encounter
Secondary NIH Patient-Reported Outcomes Measurement Information Systems (PROMIS) asthma impact scale Quality of life score for asthma. Range 0-100. A higher score equates to poorer quality of life. 6-8 days after the index EMS encounter
See also
  Status Clinical Trial Phase
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Recruiting NCT05734261 - Forced Oscillations Technique During a Metacholine Test in Children N/A
Recruiting NCT06044051 - Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma N/A
Completed NCT04896502 - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers N/A
Completed NCT03503812 - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT05547477 - Continuous EMG Measurements in Children With Asthma During Sleep
Completed NCT04388098 - Oral Health Status of Asthmatic Children
Terminated NCT03586544 - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity Phase 4
Recruiting NCT04821908 - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Enrolling by invitation NCT06239844 - Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English N/A
Recruiting NCT06003569 - Reducing Asthma Attacks in Disadvantaged School Children With Asthma N/A
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Not yet recruiting NCT05974917 - Serious gaMes as Emerging E-health Interventions for Young People With neurologicaL or rEspiratory disoRders
Recruiting NCT05366309 - Performance and Adherence in Children Using Spacers N/A
Completed NCT05684926 - COVID-19 Pandemic Asthma Child Telerehabilitation Yoga N/A
Recruiting NCT04166344 - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma N/A
Completed NCT03907410 - The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial N/A
Completed NCT03673618 - Soluble Corn Fiber Supplementation for Asthma Phase 2